Replimune (REPL) stock dips as the FDA plans an advisory committee meeting after accepting the company's marketing ...

Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Based on page view growth over the last 3 trading days Key Takeaways Replimune shares fell 54.2% in three months after the FDA issued a CRL against its RP1 BLA in July. The FDA cited shortcomings in ...

) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...

REPL EFFECT: Repl.it, an online programming and computing platform, has raised $4.5 million in a seed round led by two general partners, Marc Andreessen and Andrew Chen, from the venture capital firm ...

REPL shares soared 85.7% after FDA alignment on RP1 plus Opdivo BLA resubmission plans. Replimune plans to resubmit the BLA in the coming days. The FDA intends to prioritize review. The RP1 plus ...